Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Oncology Strategy: Take A Holistic Approach To R&D

Executive Summary

With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.


Related Content

J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology
Another Sea Change In Myeloma Promised By New Therapies, Combos
CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Tesaro Adds Runway By Out-licensing Niraparib In Prostate Cancer
Imbruvica Leads Sea Change In CLL Landscape
Kyprolis Wins Full Monotherapy OK, Broader Combo Use
BMS/AbbVie Empliciti Leaps Ahead, Wins Fast FDA Nod
Janssen/Genmab Win 1st Anti-CD38 In Multiple Myeloma


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts